NephroQuiz: muscles and bananas.
Published in Healthcare & Nursing, Genetics & Genomics, and General & Internal Medicine
A 40-year-old African American man arrived at the emergency room experiencing profound muscle weakness. Past medical history revealed sporadic muscle tightness occurring 1-3 times per week, alleviated by consuming bananas. He was not using any medications, and his family history was noteworthy for hyperthyroidism and episodes of hypokalemia in his brother and mother.
Upon presentation, vital signs were temperature 98.4°F, blood pressure 127/83 mmHg, heart rate 111 beats/minute, respiratory rate 11 breaths/ minute, and oxygen saturation 96% on room air. Physical examination revealed pronounced weakness in both upper and lower extremities (strength assessed at 0/5) with areflexia.
Laboratory results are shown in Table 1. The electrocardiogram demonstrated sinus tachycardia with prolonged QTc interval of 606 ms. Swift replacement of hypokalemia effectively alleviated his symptoms, albeit leading to transient hyperkalemia that spontaneously resolved.
|
|
||
|
Tests |
Results |
Normal range |
|
Sodium |
139 mmol/L |
132-148 mmol/L |
|
Potassium |
<1.5 mmol/L |
3.5-5 mmol/L |
|
Chloride |
105 mmol/L |
98-111 mmol/L |
|
Bicarbonate |
21 mmol/L |
23-32 mmol/L |
|
Blood Urea Nitrogen |
18 mg/dL |
10-25 mg/dL |
|
Creatinine |
0.91 mg/dL |
0.7-1.4 mg/dL |
|
Calcium |
9.3 mg/dL |
8.4-10.5 mg/dL |
|
Albumin |
3.9 g/dL |
3.5-5.0 g/dL |
|
Total protein |
7.2 g/dL |
6.6-8.7 g/dL |
|
Glucose |
90 mg/dL |
65-100 mg/dL |
|
Magnesium |
1.9 mg/dL |
1.6-2.6 mg/dL |
|
Phosphorus |
2.1 mg/dL |
2.5-4.5 mg/dL |
|
AST |
64 U/L |
5-40 U/L |
|
ALT |
153 U/L |
5-41 |
|
Bilirubin- total |
0.3 mg/dL |
0.2-1.2 mg/dL |
|
Alkaline phosphatase |
79 U/L |
40-129 U/L |
|
Random urine K/Cr ratio |
10.7 mmol/g Cr |
17-121 mmol/g Cr |
|
TSH |
< 0.006 mcIU/mL |
0.270-4.200 mcIU/mL |
|
Free T3 |
13.0 pg/mL |
2.1-4.4 pg/mL |
|
Free T4 |
3.04 ng/dL |
0.9-1.70 ng/dL |
|
Thyroid Stimulating Ig (TSI) |
3.43 IU/L |
<=0.54 IU/L |
|
Thyroid Peroxidase Ab |
62.6 IU/mL |
0.0-9.0 IU/mL |
The correct answer, link to published case and explanation will be provided in the comment section.
Click here to read the original case report, published in BMC Nephrology. We encourage discussion of the case and questions in the comments.
Follow the Topic
-
BMC Nephrology
This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With collections, you can get published faster and increase your visibility.
Novel devices in hemodialysis
BMC Nephrology invites submissions to our Collection on Novel devices in hemodialysis.
Hemodialysis is a life-saving treatment for individuals with kidney failure, but it often requires frequent visits to dialysis centers, posing challenges for patients. The development of novel devices in hemodialysis, including wearable and portable technologies, has the potential to revolutionize renal health care by offering more convenient and efficient treatment options. These devices encompass a wide range of technological advancements, such as wearable artificial kidneys, advanced dialyzers, and home-treatment solutions, aiming to improve the quality of life for patients undergoing hemodialysis.
It is important to continue advancing our collective understanding in this area to address the unmet needs of individuals with kidney failure and to enhance the accessibility and effectiveness of hemodialysis. Recent advances in novel devices have shown promising results in improving the portability and efficiency of hemodialysis, allowing for more flexible treatment schedules and reducing the burden on patients. Additionally, these innovations have the potential to lower healthcare costs and improve patient outcomes, making hemodialysis more sustainable and accessible.
Topics of interest for this Collection include, but are not limited to:
• Wearable and portable hemodialysis devices
• Technological advancements in dialysis treatment
• Impact of novel devices on patient outcomes
• Home-treatment solutions for hemodialysis
• Artificial intelligence and machine learning applications in hemodialysis monitoring and treatment optimization
• 3D printing technology for personalized dialysis device fabrication
• Telemedicine and remote monitoring for home-based hemodialysis care
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being and SDG 9: Industry, Innovation, and Infrastructure.
Publishing Model: Open Access
Deadline: Jul 29, 2025
Personalized approaches to managing hypertension in kidney patients
BMC Nephrology invites submissions to our Collection on Personalized approaches to managing hypertension in kidney patients.
Hypertension is a common comorbidity in kidney patients, contributing to the progression of renal disease and increasing the risk of cardiovascular events. Personalized approaches to managing hypertension in this population have gained attention due to the variability in treatment responses and the need to optimize patient outcomes. This Collection gathers research exploring personalized and precision medicine strategies for the regulation of blood pressure in kidney patients, addressing the pathophysiology of hypertension in the context of renal disease and considering acute and chronic kidney injury.
Advancing our collective understanding in this area is crucial for improving the management of hypertension in kidney patients, as it may lead to tailored treatment approaches that consider individual patient characteristics, such as renal function, genetic factors, and comorbidities. Recent advances have highlighted the potential of personalized treatment strategies, including the use of novel antihypertensive agents, individualized dietary interventions, and the integration of digital health technologies for remote monitoring and management of blood pressure in kidney patients.
Looking ahead, continued research in this area holds the potential for the development of innovative biomarker-based approaches for predicting treatment responses, the identification of novel therapeutic targets specific to renal hypertension, and the integration of artificial intelligence and machine learning algorithms for personalized risk prediction and treatment optimization in kidney patients with hypertension.
Topics of interest include, but are not limited to:
Personalized medicine approaches for hypertension in kidney patients
Pathophysiology of hypertension in renal disease
Long-term regulation of blood pressure in kidney patients
Precision medicine strategies for chronic kidney disease and hypertension
Role of gut microbiota in the management of hypertension in kidney patients
Impact of socioeconomic factors on personalized hypertension management in kidney patients
Novel biomarkers for predicting treatment responses in hypertensive kidney patients
Integrative omics approaches for understanding individualized responses to antihypertensive therapies in kidney patients
The influence of environmental factors on personalized hypertension management in kidney patients
This Collection supports and amplifies research related to SDG 3: Good Health and Wellbeing.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 25, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in
The correct answer is explained below:
.
.
.
.
.
The correct answer is: hypokalemic periodic paralysis.
Periodic paralysis (PP) is a rare channelopathy marked by recurrent episodes of flaccid skeletal muscle paralysis. Hypokalemic periodic paralysis (HypoPP) is categorized into familial or acquired forms. Triggers for episodes of HypoPP are primarily associated with intense exercise and high carbohydrate intake, and less frequently related to viral infections, stress, cold, salt consumption, and medications (such as glucocorticoids and insulin).
Familial HypoPP is associated with variants in the skeletal muscle sodium channel gene SCN4A in 20% of patients or the L-type calcium channel gene CACNA1S in 60% of patients. The majority of reported pathogenic variants involve arginine residues in S4 transmembrane segments, with notable hotspots at codons R528 and R1239. Generally, the existence of hyperthyroidism is more strongly associated with a diagnosis of acquired thyrotoxic periodic paralysis (TPP), with most cases occurring in Asian males without a family history of the condition. Pathogenic variants in KCNJ2 and KCNJ18 are associated with susceptibility to TPP. KCNJ2 and KCNJ18 encode Kir 2.1 and Kir2.6 respectively, inwardly rectifying potassium channels expressed in skeletal muscle and transcriptionally regulated by thyroid hormone.
Genetic testing in the discussed patient revealed a heterozygous pathogenic variant in CACNA1S [c.1583 G>A (p. R528H)] and normal sequencing of SCN4A, KCNJ2 and KCNJ18. The patient received a diagnosis of familial hypokalemic periodic paralysis and concurrent hyperthyroidism due to Graves’ disease. The likelihood of TPP in this case is reduced, given the patient is not of Asian descent, has a family history of HypoPP, and lacks identifiable variants in KCNJ2 and KCNJ18. The pathogenic variant observed in this case has been documented previously. This variant leads to a substantial reduction in the whole-cell calcium channel current and induces depolarization of the resting cell potential in response to hypokalemia.
Management of acute paralytic episodes involves maintaining proper control of serum potassium levels, necessitating vigilant monitoring for post-treatment hyperkalemia. Lifestyle and dietary modifications to avoid triggering factors are integral to treatment. Although the precise mechanism is not fully elucidated, carbonic anhydrase inhibitors have demonstrated efficacy in reducing the frequency of familiar HypoPP episodes. There is variability in the response to carbonic anhydrase inhibitors based on genotype; individuals with CACNA1S variants tend to exhibit a more favorable response compared to SCN4A variants. Additionally, the incorporation of a potassium-sparing diuretic, either in conjunction with carbonic anhydrase inhibitors or as a standalone treatment, may offer advantages for specific patients.
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x